D-0360-2022 Class II Terminated
FDA drug recall D-0360-2022 was initiated by RemedyRepack Inc. on Dec 29, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Apr 14, 2022). Affected quantity: a) 716 bottles/ 1432 capsules b) 223 blister packs/ 466 capsules.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 12, 2022
- Initiation Date
- Dec 29, 2021
- Termination Date
- Apr 14, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 716 bottles/ 1432 capsules b) 223 blister packs/ 466 capsules
Product description
Cefixime 400 mg capsule, packaged in a) 2-count bottle (NDC 70518-2749-02), b) 2-count blister pack (NDC 70518-2749-03), Rx only, MFG: Ascend Labs, LLC, Montvale, NJ 07645
Reason for recall
Failed Impurities/Degradation Specifications
Distribution pattern
Product was distributed to two direct accounts in MI and PA.
Code information
Lot #: a) B1429436-110821, Exp 07/2022; B1429434-110821, Exp 11/2022; B1429435-110821, Exp 11/2022; B1279449-072021, Exp 07/2022; B1279457-072021, Exp 07/2022; B1279442-072021,Exp 07/2022; B1057718-012621, Exp 01/2022; B1057727-012621, Exp 01/2022; b) B1358139-092121, Exp 03/2022; B1424654-110421, B1437578-111421, Exp 05/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0360-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026